XOMA (NASDAQ:XOMA) Given "Buy" Rating at HC Wainwright

XOMA (NASDAQ:XOMA - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $74.00 price objective on the biotechnology company's stock. HC Wainwright's price target would indicate a potential upside of 186.60% from the company's previous close.

Separately, SVB Leerink began coverage on shares of XOMA in a research report on Monday. They set an "outperform" rating and a $40.00 price objective on the stock.

XOMA Stock Performance

XOMA traded up $0.48 during trading on Wednesday, hitting $25.82. The company's stock had a trading volume of 13,366 shares, compared to its average volume of 20,358. The company has a quick ratio of 8.68, a current ratio of 8.68 and a debt-to-equity ratio of 1.34. XOMA has a one year low of $13.48 and a one year high of $27.00. The firm has a market cap of $300.54 million, a PE ratio of -6.39 and a beta of 0.58. The business's 50 day simple moving average is $25.06 and its 200-day simple moving average is $20.68.

XOMA (NASDAQ:XOMA - Get Free Report) last announced its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.13). The firm had revenue of $1.83 million for the quarter, compared to the consensus estimate of $1.01 million. XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. As a group, sell-side analysts predict that XOMA will post -1.73 EPS for the current fiscal year.

Hedge Funds Weigh In On XOMA

An institutional investor recently raised its position in XOMA stock. Stonepine Capital Management LLC lifted its position in XOMA Co. (NASDAQ:XOMA - Free Report) by 25.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 436,602 shares of the biotechnology company's stock after acquiring an additional 87,203 shares during the quarter. XOMA accounts for 2.0% of Stonepine Capital Management LLC's portfolio, making the stock its 12th largest position. Stonepine Capital Management LLC owned about 3.80% of XOMA worth $6,152,000 at the end of the most recent reporting period. 95.92% of the stock is currently owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.